In addition to providing glycemic control, sodium-glucose co-transporter type-2 (SGLT-2) inhibitors are known to improve the quality of life in various populations due to their benefits such as reducing hypervolemia, reducing obesity with weight loss, regulating lipid levels by increasing high-density lipoprotein (HDL) levels and decreasing triglyceride levels, and reducing hypertension (HT) [7]. This evidence concerns the gene SLC5A2 and Hypervolemia.